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Abstract Economic evaluation of vaccination is a key
tool to inform effective spending on vaccines. However,
many evaluations have been criticised for failing to capture
features of vaccines which are relevant to decision makers.
These include broader societal benefits (such as improved
educational achievement, economic growth and political
stability), reduced health disparities, medical innovation,
reduced hospital beds pressures, greater peace of mind and
synergies in economic benefits with non-vaccine inter-
ventions. Also, the fiscal implications of vaccination pro-
grammes are not always made explicit. Alternative
methodological frameworks have been proposed to better
capture these benefits. However, any broadening of the
methodology for economic evaluation must also involve
evaluations of non-vaccine interventions, and hence may
not always benefit vaccines given a fixed health-care
budget. The scope of an economic evaluation must con-
sider the budget from which vaccines are funded, and the
decision-maker’s stated aims for that spending to achieve.
Key Points for Decision Makers
Economic evaluations of vaccines usually fail to
capture all the societal benefits of vaccination.
Broadening the benefits considered must also involve
evaluations of non-vaccine interventions and hence
may not always benefit vaccines given a fixed health-
care budget.
The scope of an evaluation must consider the budget
from which vaccines are funded, and the decision-
maker’s stated aims for that spending to achieve.
1 Introduction
Vaccines are undoubtedly one of the global health success
stories of the past century, credited with saving 700,000
lives in the USA in 1994–2013 [1], and 7 million lives in
the poorest countries in 2000–2014 [2]. Spending on vac-
cination has increased dramatically. This has been driven
both by expansion in vaccine coverage worldwide, as well
as the introduction of new (but currently expensive) vac-
cines such as human papillomavirus, pneumococcal con-
jugate and meningococcal B vaccines. The cost to fully
immunise a child according to the WHO’s recommended
schedule was estimated to have risen from US$0.67 in
2001 to US$45.59 in 2014 [3]. Funding vaccination in 94
of the world’s poorest countries during the ‘‘Decade of
Vaccines’’ (2011–2020) is projected to cost over US$50
billion, but to save 25 million lives [4].
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With this increased funding has come the need to ensure
that money is well spent. Economic evaluation of vaccines
has emerged as a key tool to inform effective spending on
vaccination. The number of economic evaluations of vac-
cines has risen sharply over the last 20 years [5]. Both
national immunisation technical advisory groups [6] and
major global health funders [7, 8] consider economic evi-
dence before recommending a new vaccine. However, the
use of economic evaluation has not been without contro-
versy. Initial recommendations against introducing human
papillomavirus vaccination in Australia [9] and meningo-
coccal B vaccination in the UK [10] elicited criticism and
were eventually reversed following re-evaluations of the
underlying economic models (accompanied by negotiations
with manufacturers which may have achieved vaccine
price reductions). In contrast, in Thailand human papillo-
mavirus vaccination has not been funded to this day fol-
lowing economic analyses suggesting that it was not cost
effective at current high prices. Instead the cervical
screening programme was scaled up as it was found to be a
more cost-effective cancer prevention strategy [11].
A principal critique is that most economic evaluations
do not capture salient features of vaccines which are rele-
vant to decision makers. As a result, the full benefits of
vaccination are not adequately incorporated. This paper
discusses the challenges to standard economic evaluation
of vaccines that have been raised, the extent to which
proposed methodological changes may alter conclusions
about current vaccines and some suggested principles for
responding to these challenges.
2 Challenges to ‘‘Standard’’ Economic Evaluation
Methodology
The most common approach to economic evaluations of
vaccines (and health-care interventions more generally) is
cost-utility analysis. This aims to inform allocation of a
fixed budget in order to maximise health, measured in
terms of generic population health measures such as
quality-adjusted life years (QALYs) or disability-adjusted
life years (DALYs). This is done by comparing the incre-
mental cost effectiveness of a new intervention (such as a
vaccination programme) to a fixed threshold. The threshold
in principle represents the health foregone by reductions in
the spending on other interventions in order to fund the
new intervention.
Cost-utility analysis methods are described in guidelines
from the WHO [12] and the US Panel on Cost-Effectiveness
in Health and Medicine [13]. They are the preferred form of
economic evaluation in the majority of national guidelines
for pharmacoeconomic evaluations, which state a preference
for this issue [14]. The perspective of such analyses may be
limited to the health-care sector (as advocated by the UK’s
National Institute for Health and Care Excellence [15]), or
can extend to all costs and effects borne by society (as
advocated by the WHO [12] and the US Panel on Cost-
Effectiveness in Health and Medicine [13]).
A number of challenges to this ‘‘standard’’ approach to
economic evaluation have been made with regards to
vaccination:
2.1 Type of Analysis
Laxminarayan and co-workers suggest that benefit-cost
analysis, using value of statistical life measures to monetise
health gains, is a more comprehensive framework than
cost-utility analysis, as it also captures the non-health
benefits of vaccines [16]. According to their proposal, the
value of a life could be estimated by examining either
revealed preferences (studies of compensatory payments
for altered risk of death such as wage-risk trade-offs, i.e.
premiums paid for work in dangerous occupations) or
stated preferences (such as willingness-to-pay studies for
specific vaccines). Both these methods should in principle
capture the value people place on both health and non-
health benefits of increased life expectancy. This method-
ology has been used to value the benefit of vaccination in
developing countries in the ‘‘Decade of Vaccines’’ [17].
2.2 Fiscal Impact
Fiscal implications of vaccination programmes are not
always clear in traditional cost-effectiveness analyses
because costs are aggregated over long time horizons,
subject to discounting and presented in economic rather
than financial terms. Alternative approaches such as budget
impact and return on investment analyses can facilitate
accurate budgeting and directly address constraints of
health-care budget holders [18]. Explicit budget optimiza-
tion has been suggested as an alternative to cost-effec-
tiveness analysis particularly in countries where there is
little fiscal space to fund new interventions [19, 20].
2.3 Distribution of Health
It has been suggested that the role of economic evaluation
of vaccines should not simply be to maximise health, but to
ensure equitable distribution of health (and related benefits
such as protection from catastrophic health expenditure
associated with a serious infectious disease) [21]. These
dimensions have received greater attention following the
United Nations General Assembly’s adoption of Universal
Health Coverage as a target; this seeks to ensure that
everyone can obtain the health services they need without
having to suffer financial hardship [22].
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2.4 Broader Epidemiological Outcomes
Many vaccines have ‘‘herd’’ or indirect benefits on non-
vaccinated individuals by preventing onward transmission
in vaccinated people [23, 24]. Vaccination may also reduce
the need to prescribe antimicrobial drugs and hence reduce
antimicrobial resistance. Also, vaccines often prevent a
range of secondary outcomes besides the primary outcome
being targeted. For example, human papillomavirus vac-
cines prevent a range of non-cervical cancers and warts in
both men and women [25].
2.5 Broader Social Welfare Benefits
It has been suggested that vaccines bring about ‘‘wider
societal benefits’’ [26] by preventing disease, such as
enabling people (and their families) to contribute more
resources to society. Beyond productivity losses, there may
be an even broader set of benefits such as improved edu-
cational outcomes, reduced birth rates (because families
may decide to have fewer children when there is a greater
chance of each child surviving to adulthood), increased
household savings, macroeconomic growth and political
stability [27–29].
2.6 Supporting Innovation
Vaccine manufacturers have suggested that high-income
countries should incentivise the risky investment needed to
fund research in particularly innovative vaccines, by
allowing producers to appropriate most of the economic
surplus due to vaccine development prior to patent expiry
[10, 28].
2.7 Societal Preferences
People may place greater value on QALYs gained from
preventing an episode of severe or life-threatening illness
rather than an equivalent number of QALYs gained from
preventing many episodes of mild illness [10].
2.8 Health Service Pressures
Infections like rotavirus and influenza may cause seasonal
outbreaks during winter in temperate countries when
health-care services are already stretched [30]. The true
opportunity cost of health-care utilisation during these
times may hence be underestimated.
2.9 More Favourable Methodological Assumptions
Vaccines have features not shared by most other health
interventions, such as potentially long time lags between
the time of intervention and time of its effects (disease
prevention) [24]. Hence there have been suggestions that
current methodological guidelines around issues such as
discounting [31] disadvantage vaccines. Vaccines also
provide peace of mind to recipients and their caregivers
who are afraid of disease, which is not captured through
health measures such as QALYs and DALYs but may be
captured using techniques such as willingness-to-pay [32,
33].
2.10 Integrated Analyses with Other Interventions
Many vaccines should arguably not be evaluated as
single interventions, because they have knock-on effects
on the cost effectiveness of other (non-vaccine) inter-
ventions. For instance, human papillomavirus vaccina-
tion can reduce the number of cervical screens a woman
needs in her lifetime and hence bring considerable cost
savings [34]. Malaria vaccines have been suggested to
synergise with bed nets to produce larger health gains
than the sum total of benefits from each intervention on
its own [35].
3 Would Changing Current Methodology Affect
Economic Evaluations of Vaccines?
Table 1 shows commonly used vaccines, the results of
recent reviews of relevant economic evaluations of
vaccines, and proposed changes to economic evaluation
methodology that are particularly relevant to the vac-
cines. Most vaccines are already clearly seen to be good
value for money using standard cost-utility analysis
methodology. The traditional Expanded Programme on
Immunization (EPI) vaccines (measles, diphtheria, teta-
nus, pertussis, polio and tuberculosis) are clearly cost
effective in every country and may even be cost-saving
even from a health systems perspective [36]. More
recent vaccines such as rotavirus [37], pneumococcal
conjugate [38] and human papillomavirus [39] vaccines
are also clearly cost effective at the prices at which they
are offered to Gavi, the Vaccine Alliance, to middle-
income countries that have succeeded in negotiating
competitive prices (such as members of the Pan-Amer-
ican Health Organization [40]), and to high-income
countries with large public sector purchasers that nego-
tiate prices through competitive tenders.
Vaccination programmes for which cost-utility anal-
yses do not clearly support vaccine introduction gener-
ally fall into several categories: (1) some vaccines
targeted at particular risk groups (male human papillo-
mavirus [41] and maternal pertussis vaccination [42]),
(2) some vaccines for which the long-term ecological
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consequences are uncertain and may even be negative
(varicella [43] and 7-valent pneumococcal conjugate
[44] vaccination) and (3) some vaccines against diseases
which are extremely rare, even though they may have
severe outcomes (meningococcal group B [10] vaccina-
tion). In these situations, the outcomes of economic
evaluations often depend on the exact assumptions and
parameter values used; incorporating additional benefits
may make vaccination appear more likely to be cost
effective.
4 Considering the Decision Maker’s Objectives
Many of the proposed broader outcomes of vaccines, par-
ticularly epidemiological outcomes such as indirect pro-
tection and protection against secondary endpoints, are
already routinely incorporated into existing economic
evaluations, particularly those set in high-income countries
[10, 43, 45, 46]. Other outcomes, such as those relating to
broader societal benefits, innovation and hospital bed
pressures, are less commonly incorporated, even though
Table 1 Cost effectiveness of different vaccines (based on recent reviews), and additional benefits of those vaccines not usually included in
economic evaluations
Vaccine
(target group)
Cost effectiveness using standard methodsa Proposed benefits not
currently included
High-income
countries
Low- and middle-
income countries
Reasons if not
cost effective
Traditional
vaccines
(measles,
diphtheria,
pertussis, tetanus,
polio,
tuberculosis)
(infant)
Clearly cost effective, probably cost saving. Cost/DALY of
US$7–438 (2001 values) excluding cost savings due to
reduced health care use [36]
No studies found
suggesting the
traditional vaccine
package as a whole
is not cost-effective
Non-specific mortality
prevention [53], improved
educational achievement [54]
Haemophilus
influenzae type b
(infant)
Cost effective or cost saving in most settings in a systematic
review. Not cost effective in a few studies which assumed
low disease incidence and/or treatment costs [55]
Uncertainty about
vaccine prices and
disease incidence
[55]
Productivity gains due to
reduced sequelae and changed
household decisions [56]
Human
papillomavirus
(young adolescent
females)
Cost effective in all studies
found in a systematic
review [46]
Cost effective in most countries
in a global modelling study
[39]; cost effective in all but
one study (for Thailand) found
in a systematic review [57]
A few studies suggest
vaccination not cost
effective if prices
are very high [11]
Paid and unpaid work by
patients, changes to household
behaviour [25], reduced
frequency of cervical
screening [34]
Meningococcal
Group B (infant)
Cost effective in the UK if
the vaccine price is low
and assumptions are
favourable to the vaccine
[10]
Not examined High vaccine price,
uncertainty about
protection [10]
Preference for preventing severe
over mild diseases [10]
Pneumococcal
conjugate (infant)
Cost effective, especially
for higher-valency
vaccines, if societal costs
and/or herd protection is
included [45, 58, 59]
Cost effective if societal costs
are included [38]
Serotype replacement
(for low-valency
vaccines) [45]
(Not specifically studied)
Rotavirus (infant) Cost-effective at low
prices [60]
Cost effective [37, 60] Initial high price of
the vaccine in high-
income countries
[60]
Burden on caregivers [61], mild
episodes not leading to health-
care attendance [61], reduced
hospital bed pressure [30],
household financial risk
protection [21, 62]
Varicella (early
childhood)
Cost effective or cost
saving if either societal
perspective is taken or
without hypothesised
increase in shingles [43]
Not examined Hypothesised increase
in shingles (herpes
zoster) as a result of
decreased varicella
exposure [43]
Sick-leave compensation [43]
a Cost-effectiveness conclusions are based on views surveying literature across a range of settings and methodological assumptions. A vaccine is
considered cost effective if its incremental cost-effectiveness ratio is below a country’s gross domestic product (GDP) per capita, unless an
alternative threshold is suggested
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there is experimental and observational evidence linking
some vaccines to improved educational attainment and
reduced health disparities [29]. Evidence supporting
extrapolation of these benefits to even wider effects such as
household economic behaviour, macroeconomic growth or
national stability is weaker. However, there appears to be
no a priori reason for excluding vaccine benefits which are
grounded in evidence-based causal pathways.
However, economic evaluation methodology needs to
take into account the decision maker’s needs. The ultimate
aim of an evaluation is to increase the probability of a
decision that is aligned with the decision maker’s stated
goals about what to achieve with a given budget [47]. The
problem for vaccines is that the ‘‘decision maker’’ is often
not obvious, because there may be a separation between the
funder of a vaccination programme (such as Gavi), the
consumer (country governments who implement a vacci-
nation programme) and the beneficiary (the population of
the country, including people who are not vaccinated but
who benefit through herd protection).
In all situations, economic evaluation of vaccines must
be cognisant of the budget from which vaccines are funded.
These evaluations are conducted for a range of reasons:
advocacy (making the case for securing internal and/or
external financial resources for a vaccine) [27], selecting
the right mix of interventions to optimise the health-care
budget [19], informing tender negotiations between pur-
chasers and vaccine manufacturers [48], and ex-post
appraising the value for money of past decisions [49].
Regardless of the purpose of the analysis, the underlying
methodology and assumptions should arguably be stan-
dardised as long as vaccines are being funded out of the
same budget and with the same decision maker. This is to
ensure the most efficient outcomes are achieved from the
decision to purchase the vaccine right to final price nego-
tiations, in line with the stated goal of the decision maker.
If vaccines are funded from a health-care budget, then
the optimal use of that budget is ultimately a question of
productive rather than allocative efficiency, i.e. using the
budget so as to maximise production of the out-
come(s) desired by the budget holder [50]. For example, in
the UK, health (measured in terms of QALYs) is the
maximand for most health economic evaluations following
the National Institute for Health and Care Excellence’s
reference case [15], in part because there is no obvious way
that savings to other government departments or to the
private sector could accrue back to the health budget. In
such evaluations, the shadow price of health (represented
by the cost-effectiveness threshold) should arguably be
derived from the budgetary constraint, rather than based on
human capital arguments about the intrinsic economic
value of a healthy life year, or even individual willingness-
to-pay measures such as the value of statistical life. In
settings where the shadow price of health is unknown, and
the number of spending options are relatively limited,
budget optimisation provides an alternative analytical
framework. This is mathematically equivalent to cost-
utility analysis when applied over the entire budget, but it
could also be used to optimise selection of a subset of
potential interventions in a particular disease area [19, 20].
When vaccines are funded from fixed health-care bud-
gets, increased investment in vaccines normally involves
disinvestment from other items in the budget. Hence, any
change to the methodology used for evaluating vaccines
needs to involve broadening of the standard ‘‘reference
case’’ used for all economic evaluations. It is important to
avoid the appearance of changing methodology purely to
support the case of a particular vaccine. This kind of
‘‘special pleading’’ ultimately benefits nobody, because it
reduces the confidence that decision makers have in the
results of economic evaluations when they do not see
evidence that evaluations have discriminatory power in
identifying poor investments as well as good ones. As
Beutels and co-workers said in their commentary on
funding vaccines, ‘‘we do not plead for a special case, but
for a level playing field’’ with other interventions [24], by
ensuring that unique features of vaccines are appropriately
captured in current frameworks rather than by using sep-
arate rules for vaccines.
An overall change in economic evaluation methodology
may not always be to the advantage of vaccines if the
health budget is fixed. For instance, childhood vaccination
may indeed have broader benefits outside health in the
strict sense, in terms of child development, household
financial security and economic development. However,
the evidence linking other childhood interventions such as
malaria prevention, deworming or sanitation with some of
these benefits may be stronger than that for vaccines [29].
Similarly, increased peace of mind from protection against
infectious diseases has been mentioned as a benefit of
vaccination. However, non-vaccine health-care spending
arguably produces comparable or greater peace of mind
benefits. Examples of this are being reassured about shorter
waiting times for hospital admission (following investment
in hospital bed capacity) or availability of end-of-life care
(following investment in such care).
Alternatively, the decision maker may use the health-
care budget to optimise non-health benefits as well as
health, as is the case with most pharmacoeconomic
guidelines [14]. The scope of these broader benefits is set
by the decision maker, but if a societal perspective is taken
then there is no reason to exclude any benefit that improves
welfare [13]. Two options for this are a cost-utility analysis
with a societal perspective, and a cost-consequences anal-
ysis [51]. A cost-consequences analysis allows presentation
of outcomes that are difficult to monetise, and recognises
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that monetary benefits outside the health-care sector should
not be treated in the same way as cost savings to the health-
care provider. An example of this is the recently introduced
extended cost-effectiveness analysis, which presents indi-
cators of equity as well as efficiency [21]. However, we
must be aware that taking a wider perspective under a fixed
health-care budget will actually reduce the total health
improvement, because there will be situations in which an
intervention will be displaced by one that is less efficient in
improving health, when the latter intervention brings non-
health benefits of greater value.
If vaccination is being funded from a wider budget that
includes non-health spending, then a benefit-cost or return
on investment framework encompassing all the broader
consumption benefits of vaccines regardless of sector
would appear to ensure a level playing field, since this is
the methodology typically used to value non-health
investments. Still, there are practical considerations. In
most countries, the allocation of spending between differ-
ent ministerial budgets (such as health and education) is a
high-level political decision. Human capital arguments
about the value of increased investment in health care
generally or even vaccination specifically (such as those
made by the recent Lancet Commission on Investing in
Health [52]) may have a role in informing such allocations.
However, there are unlikely to be technical resources or
indeed even the political mandate for microeconomic
evaluations of individual programmes (such as the intro-
duction of specific vaccines) to directly inform high-level
allocations of the entire national budget.
Lastly, when a vaccination programme is being funded
in part or whole by an external government or organisation
(such as Gavi), the objective of spending is for the global
good rather than the social welfare of any particular pop-
ulation. From a global perspective, there appears to be no
justification for placing a different value on a life saved in
(for example) the UK and in Mali. However, for such
indifference to be translated into the global distribution of
health-care spending would require rich countries to accept
much larger transfers from health-care spending in their
countries to poorer countries than we are likely to see.
Hence a pragmatic way forward given limited aid budgets
is to again consider the productive efficiency question of
maximising certain welfare aims within the budget of
donor countries or organisations. For a completely altru-
istic donor, these may be aligned with the aims of local
health-care providers or the local population as a whole.
However, often vaccine funding is provided in pursuit of
externalities such as disease eradication, reduced antimi-
crobial resistance, reduced inter-country health inequalities
and greater political stability (and hence greater global
security and trade). If such outcomes are desired and can be
quantified, then they are appropriate to include in economic
evaluations in this context.
Table 2 summarises the appropriate analysis to use
depending on the objective and outcomes to include in
different situations.
5 Conclusion
Current economic evaluations exclude many of the wider
benefits of vaccines. However, this may be by design of the
economic evaluation methodology being used. Any chan-
ges to the methodology must apply equally to all health
interventions, which may not always favour greater fund-
ing for a particular vaccine. The aim of any modification
should ultimately be to ensure equal treatment for vaccines
rather than special preference.
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Health ? Cost-utility (health care perspective) or budget
optimisation
No
External
donor
Health ? externalities benefitting the global
community
? Depends on decision maker Yes (depending on decision
maker)
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